Once again in March, the pharmaceutical world saw a series of notable hires. From biotech to pharma, companies are strengthening their teams with experienced professionals.
The month of April was a bit lighter in quantity of hires, but those we did see were high-profile: pharma and biotech saw at least four CEO changes, as well as numerous board chairs.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh